Harvest Fund Management Co. Ltd Has $137,000 Stake in Encompass Health Co. (NYSE:EHC)

Harvest Fund Management Co. Ltd lowered its position in Encompass Health Co. (NYSE:EHC) by 64.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,415 shares of the company’s stock after selling 2,527 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Encompass Health were worth $137,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in Encompass Health by 1.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,819,345 shares of the company’s stock worth $156,083,000 after purchasing an additional 22,311 shares during the period. Copeland Capital Management LLC lifted its position in shares of Encompass Health by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,284,550 shares of the company’s stock valued at $124,139,000 after buying an additional 12,433 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Encompass Health by 26.0% during the 3rd quarter. Thrivent Financial for Lutherans now owns 760,496 shares of the company’s stock worth $73,494,000 after acquiring an additional 156,938 shares during the period. Magnetar Financial LLC increased its holdings in shares of Encompass Health by 1,176.6% during the 2nd quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock worth $63,899,000 after acquiring an additional 814,018 shares during the last quarter. Finally, Reinhart Partners LLC. raised its stake in Encompass Health by 2.4% in the 3rd quarter. Reinhart Partners LLC. now owns 673,040 shares of the company’s stock valued at $65,043,000 after acquiring an additional 15,550 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Price Performance

Encompass Health stock opened at $102.84 on Thursday. The stock’s fifty day moving average price is $97.53 and its two-hundred day moving average price is $91.11. Encompass Health Co. has a one year low of $63.78 and a one year high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market cap of $10.36 billion, a PE ratio of 24.84, a price-to-earnings-growth ratio of 1.35 and a beta of 0.88.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. Encompass Health’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business earned $0.86 earnings per share. As a group, research analysts expect that Encompass Health Co. will post 4.29 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a yield of 0.66%. Encompass Health’s dividend payout ratio (DPR) is 16.43%.

Analysts Set New Price Targets

EHC has been the subject of a number of research analyst reports. Truist Financial reaffirmed a “buy” rating and set a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Royal Bank of Canada upped their price target on shares of Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. KeyCorp raised their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Barclays upped their target price on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. Finally, UBS Group lifted their price target on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Encompass Health has a consensus rating of “Buy” and a consensus target price of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.